RT Journal Article
SR Electronic
A1 Shuman, Jill
T1 RFA or Antiarrythmic Drug Therapy for Symptomatic AF?
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 21
SP 22
OP 23
DO 10.1177/155989771421012
UL http://mdc.sagepub.com/content/14/21/22.2.abstract
AB Radiofrequency ablation (RFA) has emerged as an effective therapy for patients with paroxysmal atrial fibrillation (PAF) [Stabile G et al. Eur Heart J 2006], and at least 1 international consensus document concludes that ablation is an acceptable first option for patients with symptomatic PAF [Caulkins H et al. Europace 2012]. However, limited data are available comparing this technology with antiarrhythmic drug therapy as first-line treatment for patients with PAF. This article discusses 24-month outcomes from the Medical Antiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation trial [MANTRA-PAF; Cosedis Nielsen J et al. N Engl J Med 2012].